| Baricitinib for Cutaneous Dermatomyositis (NCT05361109) | University of Washington | 2022-06-01 |
| Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases (NCT05239702) | Zhejiang University | 2022-02-28 |
| An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study (NCT05192200) | Pfizer | 2021-12-20 |
| Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis (NCT04976140) | Paean Biotechnology Inc. | 2021-12-15 |
| Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation (NCT06002750) | The Third People's Hospital of Hangzhou | 2021-11-24 |
| Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis (NCT04999020) | Alexion Pharmaceuticals, Inc. | 2021-11-19 |
| Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) (NCT04723303) | University of Florida | 2021-10-06 |
| Add-on Intravenous Immunoglobulins in Early Myositis (NCT05832034) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2021-09-13 |
| Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties (NCT05027152) | Federal University of Espirito Santo | 2021-09-01 |
| High-intensity Strength Training in Myositis (NCT04486261) | Rigshospitalet, Denmark | 2021-08-30 |
| Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES (NCT07265999) | Centre Hospitalier Universitaire de la Guadeloupe | 2021-07-16 |
| An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis (NCT04946669) | The First Affiliated Hospital with Nanjing Medical University | 2021-02-01 |
| Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. (NCT04628936) | Kezar Life Sciences, Inc. | 2020-11-04 |
| Rheumatology Patient Registry and Biorepository (NCT04402086) | Yale University | 2020-08-04 |
| Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis (NCT04747652) | The First Affiliated Hospital with Nanjing Medical University | 2020-06-01 |
| A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis (NCT04033926) | Kezar Life Sciences, Inc. | 2020-01-14 |
| Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study (NCT03582800) | University Hospital, Limoges | 2020-01-06 |
| Exercise Capacity of Patients with Dermatomyosis (NCT03293615) | University Hospital, Strasbourg, France | 2019-11-28 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (NCT04044690) | CSL Behring | 2019-10-21 |
| Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders (NCT02418273) | Indiana University | 2019-08-01 |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO (NCT03816345) | National Cancer Institute (NCI) | 2019-07-16 |
| Biomarkers of Cancer-Associated Myositis (NCT06808672) | Azienda USL Reggio Emilia - IRCCS | 2019-06-13 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis (NCT03813160) | Corbus Pharmaceuticals Inc. | 2018-12-17 |
| A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis (NCT03817424) | Amgen | 2018-12-13 |
| Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis (NCT03686969) | Octapharma | 2018-08-02 |
| A Study In Adults With Moderate To Severe Dermatomyositis (NCT03181893) | Pfizer | 2018-01-23 |
| Predictor of Clinical Response to Acthar in Myositis (NCT03414086) | University of Pittsburgh | 2017-11-06 |
| Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis (NCT03267277) | National Institute of Environmental Health Sciences (NIEHS) | 2017-10-05 |
| Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis (NCT03324152) | Karolinska University Hospital | 2017-10-01 |
| Basiliximab Treating Interstitial Pneumonia of CADM (NCT03192657) | RenJi Hospital | 2017-07-01 |
| Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (NCT02971683) | Bristol-Myers Squibb | 2017-05-04 |
| Study of IFN-K in Dermatomyositis (NCT02980198) | Neovacs | 2017-05-03 |
| Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) (NCT02728752) | Octapharma | 2017-02-27 |
| Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud (NCT03027674) | Pontificia Universidad Catolica de Chile | 2016-08-01 |
| Trial of IMO-8400 in Adult Patients With Dermatomyositis (NCT02612857) | Idera Pharmaceuticals, Inc. | 2015-11-01 |
| Abatacept in Juvenile Dermatomyositis (NCT02594735) | George Washington University | 2015-11-01 |
| Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis (NCT02245841) | The Cleveland Clinic | 2015-06-15 |
| Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis (NCT02466243) | Corbus Pharmaceuticals Inc. | 2015-06-01 |
| Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study (NCT02271165) | Thomas Jefferson University | 2014-11-01 |
| Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis (NCT02043548) | Chester Oddis | 2014-10-01 |
| Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy (NCT02880527) | University Hospital, Rouen | 2014-07-01 |
| Environmental Risk Factors for Myositis in Military Personnel (NCT01734369) | National Institute of Environmental Health Sciences (NIEHS) | 2014-03-13 |
| Acthar in Treatment of Refractory Dermatomyositis and Polymyositis (NCT01906372) | Rohit Aggarwal, MD | 2013-09-01 |
| Dermatomyositis and Polymyositis Registry (NCT01637064) | Phoenix Neurological Associates, LTD | 2013-04-01 |
| Abatacept Treatment in Polymyositis and Dermatomyositis (NCT01315938) | Karolinska Institutet | 2011-01-01 |
| Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies (NCT01432613) | Assistance Publique - Hôpitaux de Paris | 2010-12-22 |
| Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis (NCT01813617) | Karolinska University Hospital | 2010-09-01 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis (NCT01148810) | Novartis Pharmaceuticals | 2010-06-15 |
| A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis (NCT01140503) | Stanford University | 2010-02-01 |
| Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) (NCT02945345) | University of Pennsylvania | 2008-06-01 |
| Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM (NCT00651040) | Institute of Rheumatology, Prague | 2008-05-01 |
| Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis (NCT01415219) | University Hospital, Lille | 2008-03-01 |
| Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) (NCT00335985) | Japan Blood Products Organization | 2006-06-01 |
| Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) (NCT00106184) | University of Pittsburgh | 2006-03-01 |
| A Pilot Study of Etanercept in Dermatomyositis (NCT00112385) | Brigham and Women's Hospital | 2006-03-01 |
| myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies (NCT00213629) | University Hospital, Rouen | 2004-11-01 |
| Anakinra in Myositis (NCT01165008) | Karolinska Institutet | 2003-09-01 |
| Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis (NCT00035958) | Children's Hospital Medical Center, Cincinnati | 2002-08-01 |
| Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis (NCT00033891) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2002-04-10 |
| Hand Function in Patients With Poly- or Dermatomyositis (NCT00866125) | Karolinska Institutet | 2002-04-01 |
| Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders (NCT00010335) | Fred Hutchinson Cancer Center | 2000-11-01 |
| Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis (NCT00005571) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2000-04-01 |
| Absorption of Corticosteroids in Children With Juvenile Dermatomyositis (NCT00004357) | Northwestern University | 1997-09-01 |
| Adult and Juvenile Myositis (NCT00017914) | National Institute of Environmental Health Sciences (NIEHS) | 1995-06-07 |
| Methimazole to Treat Polymyositis and Dermatomyositis (NCT00001421) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1995-06-01 |
| Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity (NCT03941184) | Mayo Clinic | 1995-01-01 |
| Genetic and Family Studies of Inherited Muscle Diseases (NCT00001331) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1993-05-01 |
| Study and Treatment of Inflammatory Muscle Diseases (NCT00001265) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1992-01-10 |
| Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies (NCT00001261) | National Institute of Neurological Disorders and Stroke (NINDS) | 1990-05-01 |